Read Time:30 Second
Phoenix-based Item 9 Labs Corp. said Wednesday it’ll pay an undisclosed sum to acquire Canada’s Sessions Cannabis, which generates about C$70 million in annual sales with 43 stores in Ontario. Item 9 Labs Corp. CEO Andrew Bowden said the acquisition “fast-tracks our entry into the Canadian market.” Shares of Item 9 Labs are down 9.9% in 2022, compared to a drop of 46% by the AdvisorShares Pure US Cannabis ETF .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0